TP53 and non-small cell lung carcinoma: Post hoc analysis revealed that the increase in % G2/M phase cells induced by higher concentrations of volasertib (12.5–20 nm) was less pronounced in p53 wild‐type NSCLC cells compared to cells without functional p53, at least under normoxia.